Annual report pursuant to Section 13 and 15(d)

Unaudited Quarterly Financial Information

v3.8.0.1
Unaudited Quarterly Financial Information
12 Months Ended
Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]  
Unaudited Quarterly Financial Information

13. Unaudited Quarterly Financial Information

The quarterly interim financial information shown below has been prepared by the Company’s management and is unaudited. It should be read in conjunction with the audited financial statements appearing herein.

 

     2017  
     First      Second      Third      Fourth  

Revenues

   $ —        $ —        $ —        $ —    

Total operating expenses

     1,987,656        1,396,759        1,921,520        1,412,383  

Profit (loss) from discontinued operations

     (121      121        -0-        —    

Net Loss

     (1,982,696      (1,220,866      (2,067,230      (1,460,733

Loss per share:

           

Basic and diluted net loss per share from continuing operations

   $ (0.40    $ (0.25    $ (0.42    $ (0.30

Basic and diluted net profit per share from discontinued operations

   $ 0.00      $ 0.00      $ 0.00      $ 0.00  
     2016  
     First(1)      Second      Third      Fourth  

Revenues

   $ —        $ —        $ —        $ —    

Total operating expenses

     2,074,645        1,733,282        2,026,670        2,707,908  

Profit from discontinued operations

     11,113        1,420,947        42,566        9,386  

Net Loss

     (2,062,885      (312,615      (1,963,007      (2,674,797

Loss per share:

           

Basic and diluted net loss per share from continuing operations

   $ (0.52    $ (0.43    $ (0.41    $ (0.55

Basic and diluted net profit per share from discontinued operations

   $ 0.00      $ 0.35      $ 0.01      $ 0.00  

 

(1) Certain amounts previously reported as revenue, cost of revenue, research and development, selling, general and administrative relating to the consumer probiotic business is now reported as profit (loss) from discontinued operations.